Targeted Demethylation to Enhance Response or Overcome Resistance to EGFR Blocking Agents in KRAS Wild-Type Metastatic Colorectal Cancer Patients Using Sequential Decitabine and Panitumumab.
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2013
At a glance
- Drugs Decitabine (Primary) ; Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 10 Jun 2017 Biomarkers information updated
- 22 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov record.
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.